Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Columnists


Search by Name:

About Stefan Feulner

Stefan Feulner
Stefan Feulner, Apaton
Stefan is a seasoned fund advisor with over 20 years of experience in the capital markets. He is passionate about emerging trends in e-commerce, fintech, blockchain, and artificial intelligence, staying at the forefront of innovation to provide strategic guidance and insights. His expertise allows him to identify growth opportunities and navigate the complexities of these evolving sectors.


Stefan Feulner's Most Recent Articles

Almonty Industries – Escalation level raised

China's tungsten dominance risks global supply chains. Almonty Industries' Sangdong mine to boost...

Stefan Feulner | April 22, 2025

BYD, dynaCERT, thyssenkrupp - Trump rollercoaster creates opportunities

Discover dynaCERT's innovative HydraGEN™ technology, a game-changer for fuel efficiency and...

Stefan Feulner | April 14, 2025

Porr AG, Globex Mining, Strategy – Exaggerated panic

Market panic following U.S. tariffs hits global stocks, with Porr AG, Globex Mining, and Strategy...

Stefan Feulner | April 7, 2025

Agnico Eagle, Desert Gold, and Harmony Gold – 3 Favorites for the gold boom

Agnico Eagle accelerates its acquisition spree, Desert Gold Ventures heats up the scene, and...

Stefan Feulner | April 1, 2025

BioNTech & Cardiol Therapeutics – on the verge of a breakout

BioNTech and Pfizer suffers a defeat in a patent dispute, and Cardiol Therapeutics expects...

Stefan Feulner | May 22, 2024

Featured Company